title: A common variant of the endothelial nitric oxide synthase (Glu298-->Asp) is a major risk factor for coronary artery disease in the UK.
abstract: BACKGROUND
  Endothelium-derived nitric oxide (NO) is synthesised from L-arginine by endothelial nitric oxide synthase (eNOS) encoded by the NOS 3 gene on chromosome 7. Because reduced NO synthesis has been implicated in the development of coronary atherosclerosis, which has a heritable component, we hypothesised that polymorphisms of NOS 3 might be associated with increased susceptibility to this disorder.
  
  
  RESULTS
  Single-strand conformation polymorphism analysis of NOS 3 identified a G-->T polymorphism in exon 7 of the gene which encodes a Glu-->Asp amino acid substitution at residue 298 of eNOS. We investigated the relationship between this Glu(298)-->Asp variant and atherosclerotic coronary artery disease (CAD) using 2 independent case-controlled studies. In the first study (CHAOS), cases consisted of 298 unrelated patients with positive coronary angiograms and controls were 138 unrelated healthy individuals ascertained through a population health screen. In the second study (CHAOS II), the cases were 249 patients with recent myocardial infarction (MI), and a further 183 unrelated controls. There was an excess of homozygotes for the Asp298 variant among patients with angiographic CAD, and among patients with recent MI when compared with their respective controls (35.9% versus 10.2%, P<0.0001 in CHAOS, and 18.1% versus 8.7%, P<0.02 in CHAOS II). In comparison to Glu(298) homozygotes, homozygosity for Asp(298) was associated with an odds ratio of 4.2 (95% CI, 2.3 to 7.9) for angiographic CAD and 2.5 (95% CI, 1.3 to 4.2) for MI.
  
  
  CONCLUSIONS
  Homozygosity for a common NOS 3 polymorphism (894 G-->T) which encodes a Glu298-->Asp amino acid substitution in eNOS is a risk factor for angiographic CAD and recent MI in this population.
authors.affiliation: Clinical Pharmacology Unit, University of Cambridge Clinical School, Box 110, Addenbrooke's Hospital, Cambridge, UK.
authors.forename: A D
authors.initials: AD
authors.lastname: Hingorani
authors.forename: C F
authors.initials: CF
authors.lastname: Liang
authors.forename: J
authors.initials: J
authors.lastname: Fatibene
authors.forename: A
authors.initials: A
authors.lastname: Lyon
authors.forename: S
authors.initials: S
authors.lastname: Monteith
authors.forename: A
authors.initials: A
authors.lastname: Parsons
authors.forename: S
authors.initials: S
authors.lastname: Haydock
authors.forename: R V
authors.initials: RV
authors.lastname: Hopper
authors.forename: N G
authors.initials: NG
authors.lastname: Stephens
authors.forename: K M
authors.initials: KM
authors.lastname: O'Shaughnessy
authors.forename: M J
authors.initials: MJ
authors.lastname: Brown
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D017023:Coronary Angiography; D003327:Coronary Disease / Q000209:etiology* / Q000235:genetics; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000235:genetics; D019001:Nitric Oxide Synthase / Q000235:genetics*; D052250:Nitric Oxide Synthase Type III; D011110:Polymorphism, Genetic; D012307:Risk Factors
chemical_list: C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III